Latest STSA reports update at 2023-05-11: 2023-Q1 ∙ 2022-Q4 ∙ 2022-Q1

Satsuma Pharmaceuticals STSA

$ 1.1 -0.9%

Satsuma Pharmaceuticals Balance Sheet 2011-2024 | STSA

Annual Balance Sheet Satsuma Pharmaceuticals

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-33.3 M	-17.8 M	-240 K	-1.56 M	-	-	-	-	-	-
Long Term Debt	-	-	1.04 M	2.95 M	4.82 M	94 K	-	-	-	-	-	-
Long Term Debt Current	138 K	1.08 M	1.99 M	1.98 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	1.05 M	2.97 M	16.5 M	5.72 M	-	-	-	-	-	-
Total Current Liabilities	8.12 M	8.49 M	8.05 M	7.97 M	-	-	-	-	-	-	-	-
Total Liabilities	8.12 M	8.49 M	9.1 M	10.9 M	18.5 M	7.42 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-212 M	-142 M	-90.6 M	-43 M	-14.8 M	-7.48 M	-	-	-	-	-	-
Total Assets	54.9 M	110 M	81 M	126 M	6.38 M	1.98 M	-	-	-	-	-	-
Cash and Cash Equivalents	16.4 M	15.8 M	36.3 M	22.8 M	5.2 M	-	-	-	-	-	-	-
Book Value	46.8 M	101 M	71.9 M	115 M	-12.1 M	-5.43 M	-	-	-	-	-	-
Total Shareholders Equity	46.8 M	101 M	71.9 M	115 M	-12.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Satsuma Pharmaceuticals

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	70 K	104 K	833 K	1.33 M	1.83 M	333 K	2.83 M	3.33 M	3.83 M	4.33 M	4.83 M	5 M	2.95 M	2.95 M	4.82 M	4.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	5.83 M	8.12 M	6.66 M	7.96 M	6.69 M	8.49 M	6.62 M	7.58 M	5.91 M	9.1 M	9.1 M	9.1 M	9.1 M	10.9 M	10.9 M	10.9 M	10.9 M	6.86 M	6.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-222 M	-212 M	-189 M	-174 M	-157 M	-142 M	-126 M	-113 M	-101 M	-90.6 M	-90.6 M	-90.6 M	-90.6 M	-43 M	-43 M	-43 M	-43 M	-14.8 M	-14.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	43.5 M	54.9 M	75 M	80.2 M	93.7 M	110 M	122 M	135 M	144 M	81 M	81 M	81 M	81 M	126 M	126 M	126 M	126 M	6.38 M	6.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	19.5 M	16.4 M	40.6 M	23.8 M	21.4 M	15.8 M	42.3 M	53.9 M	102 M	36.3 M	36.3 M	36.3 M	36.3 M	22.8 M	22.8 M	22.8 M	22.8 M	5.2 M	5.2 M	-	-	1.66 M	-	-	-	6.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	37.6 M	46.8 M	68.4 M	72.2 M	87 M	101 M	116 M	128 M	138 M	71.9 M	71.9 M	71.9 M	71.9 M	115 M	115 M	115 M	115 M	-484 K	-484 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	37.6 M	46.8 M	68.4 M	72.2 M	87 M	101 M	116 M	128 M	138 M	71.9 M	71.9 M	71.9 M	71.9 M	115 M	115 M	115 M	115 M	-12.1 M	-12.1 M	-8.27 M	-	-5.43 M	-	-	-	-326 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency